Evidence map›Paper›PMID 34372912›Full record

ReviewJournal of experimental & clinical cancer research : CR2021

Cellular based immunotherapy for primary liver cancer.

Yuanyuan Zheng, Yan Li, Jiao Feng, Jingjing Li, Jie Ji, Liwei Wu, Qiang Yu, Weiqi Dai, Jianye Wu, Yingqun Zhou and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of experimental & clinical cancer research : CR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Yuanyuan ZhengDepartment of Gastroenterology, Putuo People's Hospital, Tongji University, Shanghai, 200060, China.
Yan LiDepartment of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Jiao FengDepartment of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Jingjing LiDepartment of Gastroenterology, Putuo People's Hospital, Tongji University, Shanghai, 200060, China.
Jie JiDepartment of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Liwei WuDepartment of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Qiang YuDepartment of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Weiqi DaiDepartment of Gastroenterology, Putuo People's Hospital, Tongji University, Shanghai, 200060, China.
Jianye WuDepartment of Gastroenterology, Putuo People's Hospital, Tongji University, Shanghai, 200060, China. wjymail@163.com.
Yingqun ZhouDepartment of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China. yqzh02@163.com.
Chuanyong GuoDepartment of Gastroenterology, Putuo People's Hospital, Tongji University, Shanghai, 200060, China. guochuanyong@hotmail.com.ORCID http://orcid.org/0000-0002-6527-4673
Tongji University · CN

Funding

Chinese Foundation for Hepatitis Prevention and Control (CN) No. CFHPC2019031Health System Innovation Project of Shanghai Putuo Science and Technology Commission No. PTKWWS201801, No. PTKWWS201903National Natural Science Foundation of China No. 82002539Natural Science Foundation of Shanghai No. 19ZR1447700Yangfan Project of Shanghai Science and Technology Commission No. 20YF1443300
6 · The paper itself

Abstract

Primary liver cancer (PLC) is a common malignancy with high morbidity and mortality. Poor prognosis and easy recurrence on PLC patients calls for optimizations of the current conventional treatments and the exploration of novel therapeutic strategies. For most malignancies, including PLC, immune cells play crucial roles in regulating tumor microenvironments and specifically recognizing tumor cells. Therefore, cellular based immunotherapy has its instinctive advantages in PLC therapy as a novel therapeutic strategy. From the active and passive immune perspectives, we introduced the cellular based immunotherapies for PLC in this review, covering both the lymphoid and myeloid cells. Then we briefly review the combined cellular immunotherapeutic approaches and the existing obstacles for PLC treatment.

Indexed as

HumansImmunotherapyLiver NeoplasmsCellular based immunotherapyCombined immunotherapyLymphoid cellMyeloid cellPrimary liver cancer

Identifiers

PMID34372912
PMCPMC8351445
OpenAlexW3189657553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.